Related Experiment Videos
Pharmacogenetic determinants of anti-cancer drug activity and toxicity
R Danesi1, F De Braud, S Fogli
1Division of Pharmacology and Chemotherapy, Dept of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, 55 Via Roma, 56126 Pisa, Italy. r.danesi@med.unipi.it
Abstract:
Cellular responses to anti-cancer agents result from the interaction between drugs, cellular targets and mechanisms of damage repair. Despite the pharmacological advances in the treatment of cancer, the clinical efficacy of chemotherapy is unpredictable in most patients. However, new information on the genetics of cancer delineates strategies by which the genetic background of tumour cells and patients might be profiled to select anti-cancer agents with improved efficacy and tolerability. This article focuses on the application of pharmacogenetics in the characterization of differences in the pharmacokinetics and pharmacodynamics of anti-cancer agents among individuals to define the likelihood of response and reduce the incidence of adverse effects.
Insights
Pharmacogenetics profiles individual genetic differences to predict patient response to anti-cancer drugs. This approach aims to improve chemotherapy efficacy and reduce adverse effects by tailoring treatments.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Cellular response to anti-cancer drugs involves complex interactions between medications, cellular targets, and repair mechanisms.
- Current chemotherapy efficacy is often unpredictable, highlighting a need for personalized treatment strategies.
- Advances in cancer genetics offer opportunities to profile patients and tumor cells for better drug selection.
Purpose of the Study:
- To explore the application of pharmacogenetics in optimizing anti-cancer agent selection.
- To characterize inter-individual variability in pharmacokinetics and pharmacodynamics of chemotherapy drugs.
- To enhance prediction of patient response and minimize adverse effects.
Main Methods:
- Review of current literature on pharmacogenetics in oncology.
- Analysis of genetic profiling strategies for tumor cells and patients.
- Examination of pharmacokinetic and pharmacodynamic variability in anti-cancer drug response.
Main Results:
- Pharmacogenetics enables the characterization of individual differences in drug metabolism and action.
- Genetic profiling can identify patients likely to respond to specific anti-cancer agents.
- Personalized approaches can improve treatment outcomes and reduce toxicity.
Conclusions:
- Pharmacogenetics is a key strategy for personalizing cancer therapy.
- Tailoring anti-cancer treatments based on genetic profiles improves efficacy and tolerability.
- Integrating pharmacogenetics into clinical practice is crucial for advancing cancer care.